123 related articles for article (PubMed ID: 10404773)
1. Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thiozyloside compound.
Masson P; Theveniaux J; Coup D; Grégoire T; Vaillot M; Dupouy D; Sié P; Boneu B; Millet J
Thromb Haemost; 1999 Jun; 81(6):945-50. PubMed ID: 10404773
[TBL] [Abstract][Full Text] [Related]
2. The venous antithrombotic profile of naroparcil in the rabbit.
Millet J; Theveniaux J; Brown NL
Thromb Haemost; 1994 Dec; 72(6):874-9. PubMed ID: 7740457
[TBL] [Abstract][Full Text] [Related]
3. The effect of the beta-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbit.
Masson PJ; Coup D; Millet J; Brown NL
J Biol Chem; 1995 Feb; 270(6):2662-8. PubMed ID: 7852334
[TBL] [Abstract][Full Text] [Related]
4. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
5. Basic and clinical study on the antithrombotic mechanism of glycosaminoglycan extracted from sea cucumber.
Li Z; Wang H; Li J; Zhang G; Gao C
Chin Med J (Engl); 2000 Aug; 113(8):706-11. PubMed ID: 11776053
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
[TBL] [Abstract][Full Text] [Related]
8. Venous antithrombotic and anticoagulant activities of a fucoïdan fraction.
Mauray S; Sternberg C; Theveniaux J; Millet J; Sinquin C; Tapon-Bretaudière J; Fischer AM
Thromb Haemost; 1995 Nov; 74(5):1280-5. PubMed ID: 8607110
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic and biochemical profiles of new venous antithrombotic beta-D-xyloside derivatives: potential antiathero/thrombotic drugs.
Martin NB; Masson P; Sepulchre C; Theveniaux J; Millet J; Bellamy F
Semin Thromb Hemost; 1996; 22(3):247-54. PubMed ID: 8836009
[TBL] [Abstract][Full Text] [Related]
10. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
Halldórsdóttir AM; Zhang L; Tollefsen DM
Glycobiology; 2006 Aug; 16(8):693-701. PubMed ID: 16624894
[TBL] [Abstract][Full Text] [Related]
11. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
[TBL] [Abstract][Full Text] [Related]
12. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
13. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
[TBL] [Abstract][Full Text] [Related]
14. A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits.
Chan AK; Berry L; Klement P; Julian J; Mitchell L; Weitz J; Hirsh J; Andrew M
Blood Coagul Fibrinolysis; 1998 Oct; 9(7):587-95. PubMed ID: 9863706
[TBL] [Abstract][Full Text] [Related]
15. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis.
Toulon P; Vitoux JF; Fiessinger JN; Sicard D; Aiach M
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):435-9. PubMed ID: 1718466
[TBL] [Abstract][Full Text] [Related]
16. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
[TBL] [Abstract][Full Text] [Related]
17. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
19. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
20. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
